SJS Respiratory Injury Help in California: Fight Back

Understanding SJS, TEN, and Respiratory Complications

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare but severe, often medication-related hypersensitivity reactions that damage skin and mucous membranes. When the respiratory tract is involved, patients may experience painful mouth and throat lesions, airway swelling, bronchial sloughing, pneumonia, acute respiratory distress, and scarring that can lead to chronic cough, wheezing, and reduced lung capacity. These complications may require hospitalization, ICU care, intubation, and long-term pulmonary follow-up (see StatPearls; DermNet).

Who May Be Responsible

Responsibility depends on the facts and evidence:

• Pharmaceutical manufacturers: Potential claims may include failure to warn and, in some contexts, strict liability theories. In California, failure-to-warn claims against brand-name manufacturers are recognized in appropriate cases, while design-defect claims for prescription drugs are generally limited under state law (see Brown v. Superior Court; Carlin v. Superior Court).
• Healthcare providers: Medical malpractice (professional negligence) claims may be viable where prescribing, monitoring, or recognition and response to SJS/TEN symptoms fell below the applicable standard of care.
• Pharmacies or distributors: Potential liability can arise for dispensing errors or other negligent acts; duties and defenses vary by facts.
• Important federal preemption considerations: Claims against generic drug manufacturers may be limited by federal preemption (see PLIVA, Inc. v. Mensing; Mutual Pharm. v. Bartlett). Failure-to-warn claims against brand-name manufacturers are generally not preempted in many circumstances (see Wyeth v. Levine), and California recognizes certain theories allowing claims related to brand-name warnings even when a generic was taken, depending on the facts (see Conte v. Wyeth; T.H. v. Novartis).

Identifying proper defendants requires expert review of medication history, timing of symptoms, warnings, and clinical course.

Key Evidence That Strengthens SJS Respiratory Claims

• Medical records confirming SJS/TEN diagnosis, extent of skin and mucosal involvement, and respiratory findings (bronchoscopy, imaging, ICU notes).
• Medication timeline: drugs started within the risk window before symptom onset (e.g., certain antibiotics, anti-seizure drugs, NSAIDs, or other high-risk agents identified in literature and labeling).
• Pathology/biopsy and dermatology consults supporting SJS/TEN.
• Pulmonary function tests and imaging showing acute injury and long-term impairment.
• Drug labeling and published evidence showing known risks and warnings.
• Expert opinions (dermatology, pulmonology, pharmacology) causally linking the drug exposure to SJS/TEN and respiratory harm.

California Legal Theories Commonly Used

• Products liability: Failure to warn (often against brand-name manufacturers), with design-defect and manufacturing-defect theories evaluated case-by-case. California limits strict-liability design-defect claims for prescription drugs, so claims frequently focus on warnings and negligence (see Brown; Carlin).
• Negligence and negligent failure to warn.
• Medical malpractice (professional negligence) against healthcare providers if care fell below the standard of care.
• Breach of warranty or consumer protection claims where appropriate.

California practice often permits pleading multiple theories in the alternative while discovery clarifies the facts.

Damages You May Seek

• Medical costs: hospitalization/ICU, pulmonology and dermatology care, respiratory therapy, medications, and future care needs.
• Lost income and reduced earning capacity.
• Pain and suffering and loss of enjoyment of life.
• Wrongful death: funeral expenses and losses recoverable by eligible family members (see CCP § 377.60).
• Punitive damages in limited circumstances where clear and convincing evidence shows malice, oppression, or fraud (see Civ. Code § 3294).

Filing Deadlines and Why Timing Matters

California imposes strict filing deadlines that vary by claim type and facts. Missing a deadline can bar recovery. Examples (exceptions and tolling may apply):

• Personal injury/product liability: generally two years from injury (see CCP § 335.1).
• Medical malpractice: generally one year from discovery (or three years from injury), whichever occurs first, subject to statutory exceptions (see CCP § 340.5).
• Claims against government entities: administrative claim usually required within six months in many cases (see Gov. Code § 911.2).

Because SJS/TEN timelines can be complex, consult a lawyer promptly to calculate and preserve all deadlines correctly.

What To Do If You Suspect SJS Caused Respiratory Injury

• Seek immediate medical care and follow specialist guidance.
• Preserve medication bottles, pharmacy printouts, and discharge summaries.
• Keep a symptom diary and copies of imaging, bronchoscopy reports, and pulmonary testing.
• Avoid stopping or changing medications without medical advice—coordinate with your doctors.
• Contact a California attorney experienced in SJS/drug injury cases to evaluate potential claims and protect your rights.

How Our California Team Helps

• Rapid investigation of drug exposures, hospital records, and potential defendants.
• Coordination with medical experts to document causation and respiratory harm.
• Preservation of evidence and timely filing before applicable deadlines expire.
• Negotiation with insurers and manufacturers and, when necessary, litigation in California courts.
• No-cost consultation; many matters handled on a contingency fee where allowed—no fee unless we obtain a recovery. Court costs and case expenses may be client-responsible if not recovered.

Get a Free Case Review

If you or a loved one suffered SJS or TEN with respiratory complications after taking a medication in California, contact us. We can review your case, explain your options, and help you pursue appropriate compensation.

Sources

• StatPearls: Stevens-Johnson Syndrome (Toxic Epidermal Necrolysis)
• DermNet: Toxic epidermal necrolysis
• Brown v. Superior Court (Abbott Labs), 44 Cal.3d 1049 (1988)
• Carlin v. Superior Court, 13 Cal.4th 1104 (1996)
• Wyeth v. Levine, 555 U.S. 555 (2009)
• PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011)
• Mutual Pharm. Co. v. Bartlett, 570 U.S. 472 (2013)
• Conte v. Wyeth, Inc., 168 Cal.App.4th 89 (2008)
• T.H. v. Novartis Pharm. Corp., 4 Cal.5th 145 (2017)
• California Code of Civil Procedure § 335.1
• California Code of Civil Procedure § 340.5
• California Government Code § 911.2
• California Civil Code § 3294
• California Code of Civil Procedure § 377.60

California-specific notice

Attorney advertising. This information is general and reflects California law as of the date shown. It is not legal or medical advice and does not create an attorney-client relationship. Outcomes and deadlines depend on your specific facts; consult a qualified California attorney.